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M A J O R A R T I C L E
Rare, Highly Pyrimethamine-Resistant Alleles
of the Plasmodium falciparum Dihydrofolate
Reductase Gene from 5 African Sites
Sarah J. Bates,1 Peter A. Winstanley,2 William M. Watkins,2 Ali Alloueche,3 Juma Bwika,4 T. Christian Happi,5
Peter G. Kremsner,6 James G. Kublin,7,a Zul Premji,8 and Carol Hopkins Sibley1
1Department of Genome Sciences, University of Washington, Seattle; 2Department of Pharmacology and Therapeutics, University of Liverpool,
Liverpool, and 3London School of Hygiene and Tropical Medicine, London, United Kingdom; 4Centre for Geographical Medicine, Kenya Medical
Research Institute, Kilifi, Kenya; 5Malaria Research Laboratories, Institute for Advanced Medical Research and Training, College of Medicine,
University of Ibadan, Ibadan, Nigeria; 6Department of Parasitology, Institute of Tropical Medicine, University of Tu¨bingen, Tu¨bingen, Germany,
and Medical Research Unit, Albert Schweitzer Hospital, Lambare´ne´, Gabon; 7The Malawi-Liverpool-Wellcome Trust Programme for Tropical
Medicine Research, Chichiri, Blantyre, Malawi; 8Department of Parasitology/Medical Entomology, School of Public Health and Social Sciences,
Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania
In eastern and southern Africa, there has been a rapid increase in the prevalence of alleles with mutations in
the Plasmodium falciparum dihydrofolate reductase gene (dhfr) associated with increased risk of clinical failure
of sulfadoxine-pyrimethamine (S/P). Molecular methods for surveillance of these mutations are now wide-
spread, but the usual analysis detects only the most prevalent allele in a polyclonal sample. We used a yeast-
expression system to identify rare, highly pyrimethamine-resistant alleles of dhfr in isolates from 5 African
countries—Kenya, Tanzania, Malawi, Gabon, and Nigeria. Only the isolates from Nigeria yielded significant
numbers of novel resistant alleles, and only 1 of the alleles from any location showed a 13-fold increase in
resistance to S/P or to chlorproguanil-dapsone. Overall, these results suggest that dhfr alleles that confer high
levels of resistance to antifolates are rare, even in eastern and southern Africa, where pyrimethamine has been
intensively used.
As the effectiveness of chloroquine for treatment of
Plasmodium falciparum infections has decreased, coun-
tries in Africa have shifted to sulfadoxine-pyrimeth-
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amine (S/P) as the recommended treatment. Malawi
made that change in 1993, and other countries in east-
ern and southern Africa have recently followed suit [1,
2]. The pyrimethamine component of S/P is a com-
petitive inhibitor of the essential enzyme dihydrofo-
late reductase (DHFR; Enzyme Commission number
1.5.1.3), and sulfadoxine inhibits dihydropteroate syn-
thase (DHPS; Enzyme Commission number 2.5.1.15),
a key enzyme in folate biosynthesis [3]. Point mutations
in the dhfr gene are the principal mode by which re-
sistance to pyrimethamine evolves. The ease of molec-
ular analysis by polymerase chain reaction (PCR) has
produced substantial literature on the prevalence of the
polymorphisms in P. falciparum dhfr that are respon-
sible for resistance to pyrimethamine [3–18]. The most
common mutation correlated with resistance to pyri-
methamine is a change from serine to asparagine at
codon 108 (S108N) [19, 20], and additional mutations
at codons 51 and 59 progressively increase the resistance
to pyrimethamine [3, 21–23].
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In many sites in eastern and southern Africa, there has been
a rapid increase in the prevalence of the 51I/59R/108N triple
alleles, and this change is associated with an increased risk of
clinical failure of treatment with S/P [11, 14, 15, 24–30]. The
increasing failure of S/P stimulated the development of chlor-
proguanil-dapsone (LapDap; GlaxoSmithKline). Like S/P, this
drug is a combination: chlorcycloguanil, the metabolite of
chlorproguanil, inhibits DHFR, and dapsone inhibits DHPS.
Chlorproguanil-dapsone is clinically effective, even in areas
where resistance to S/P is high [24, 25, 31–33], and it has
recently been introduced in a number of countries [34]. Par-
asites that carry dhfr alleles with 1 additional mutation, an
isoleucine-to-leucine change at codon 164 (51I/59R/108N/
164L), are no longer sensitive to S/P or chlorproguanil-dapsone
[35]. These quadruple mutants became common in Southeast
Asia after only ∼6 years of S/P use, and new drugs were required
for treatment [36].
In many sites, polyclonal infections are common, and the
sensitivity of the standard PCR [37] is not sufficient to detect
alleles that include less than ∼10% of the parasites in an isolate.
If molecular analysis is to be useful as an early warning of rare
but potentially highly drug-resistant alleles, then methods for
their detection at very low levels are needed. We have used a
yeast-expression system [38, 39] to rapidly screen samples iso-
lated from patients in 5 African countries—Kenya, Tanzania,
Malawi, Gabon, and Nigeria.
METHODS
The P. falciparum DNA examined was collected as part of the
phase 3 safety and efficacy trial comparing the new, fixed-com-
bination antifolate drug chlorproguanil-dapsone with S/P [34].
This was a double-blind, placebo-controlled study, with 1480
patients in the chlorproguanil-dapsone arm and 370 patients
in the S/P arm. The samples were collected between March and
December 2000 at 5 sites: Kisarawe (Tanzania), Kilifi (Kenya),
Blantyre (Malawi), Lambare´ne´ (Gabon), and Ibadan (Nigeria).
The samples examined in the present study were blood spots
from 25 patients who were judged by use of microscopy to
have parasites on day 14 after their initial treatment. Samples
obtained before treatment (day 0) and at day 14 were analyzed
for each patient. Informed consent was obtained from all pa-
tients or their parents for the study from which these samples
derived. The study met both US Department of Health and
Human Services guidelines and the guidelines established by
the home institutions in each study site. Permission was granted
for analysis of the parasite DNA in our laboratory.
Genomic P. falciparum DNA was initially extracted from
dried blood spots on filter paper by use of methanol precipi-
tation or by use of the blood sample DNA extraction protocol
from a commercial kit (QIAamp; QIAGEN). The dhfr gene was
amplified by use of PCR with PfuTurbo polymerase (Strata-
gene) with proofreading activity, to minimize replication errors
during PCR. Samples that yielded interesting alleles were re-
analyzed and resequenced to ensure that the alleles were not
PCR artifacts. The 50-mL reaction contained 1 mL of PfuTurbo
polymerase, 1 PCR buffer, 0.5 mmol/L each primer, 0.4 mmol/
L dNTPs, and 5–10 mL of template DNA. The 5′ primer used
was CTCCTTTTTATGATGGAACAAGTCTGCGACGTTTTCG,
and the 3′ primer used was TCATATGACATGTATCTTTGTCA-
TCATTCTTTAAAGGC. The cycling parameters were as follows:
initial denaturation for 3 min at 94C, 30 cycles of denaturation
for 30 s at 94C, annealing for 45 s at 50C, elongation for 1
min at 72C, and final extension for 10 min at 72C. For each
amplification, a water control was performed and transformed
into yeast; these yielded no colonies, confirming that no con-
tamination had occurred during the PCRs.
The Saccharomyces cerevisiae yeast strain TH5 lacks endoge-
nous DHFR activity and has been described elsewhere [39]. The
yeasts were transformed with a gapped plasmid GR7 [8, 39] and
the linear dhfr products of the PCR by use of a high-efficiency
lithium acetate protocol [40]. Transformants were plated onto
medium lacking tryptophan and deoxythymidine monophos-
phate. Colonies were arrayed on master plates and sequentially
replica-plated onto plates containing rich medium and 5104
mol/L pyrimethamine dissolved in DMSO (Pierce) and onto
control plates with rich medium and DMSO only. The drug
concentration was determined to allow growth of only the col-
onies that were more resistant to pyrimethamine than those that
expressed the 51I/59R/108N dhfr genotype. In addition, 5 un-
selected isolates from each sample were chosen at random from
plates containing no drug and were processed for automated
sequencing (MegaBACE; Amersham Biosciences).
The IC50 assays were performed to obtain quantitative mea-
sures of drug sensitivity, as described elsewhere [38]. In brief,
the growth of the yeast in this assay depends on the resistance
to antifolate of the dhfr allele expressed. Yeasts were grown in
96-well plates in pyrimethamine or chlorcycloguanil (0–5104
mol/L) or WR99210 (0–105 mol/L) (all drugs were a gift from
Jacobus Pharmaceutical). The growth of the yeast in each well
was assessed by reading the optical density at 650 nm after ∼24
h of incubation at 30C. The numerical IC50 value was calculated
from the slope and intercept of the line defined by the 2 data
points that bracket 50% relative growth. IC50 assays were per-
formed at least twice for each allele, to ensure reproducibility.
RESULTS
The aim of the present study was to identify rare alleles of dhfr
that encode enzymes with a very high level of resistance to
pyrimethamine. The samples examined were from patients in
the phase 3 trial of the new antifolate combination, chlorpro-
guanil-dapsone [34]. The 25 patients studied were treated with
either S/P or chlorproguanil-dapsone and remained parasite-
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Figure 1. The overall plan for the study. Day-0 and day-14 isolates from
the 25 patients who still retained parasites 14 days after treatment with
either chlorproguanil-dapsone or sulfadoxine-pyrimethamine were studied
as indicated.
mic 14 days after treatment. Parasite DNA from both the day-
0 and the day-14 samples was isolated, and the dhfr domain
of the dhfr-ts gene was amplified and integrated into a yeast
shuttle plasmid by homologous recombination. The centromere
on the plasmid ensures that each resulting yeast colony contains
only 1 dhfr allele, allowing for the unambiguous identification
of individual alleles from samples that are polyclonal. The basic
strategy is outlined in figure 1.
The standard allele-specific oligonucleotide or restriction-
digestion methods [37] identify alleles that are present at a
frequency of ∼10%, but our goal was to detect rare resistant
alleles. Both approaches use PCR, but our emphasis on rare
alleles made it crucial to ensure that we did not generate these
rare alleles in the amplification reaction. To test this, we am-
plified the triple-mutant allele (51I/59R/108N) with the high-
fidelity polymerase, PfuTurbo, cloned the products of the reaction
into yeast, and screened the resulting colonies with the same
protocol used for analysis of the field samples. We screened 1100
individual colonies on plates with mol/L pyrimeth-45 10
amine. This level of drug was chosen to allow growth of colonies
that are only slightly more resistant than those with the 51I/
59R/108N allele, to ensure that we did not miss any alleles that
fell into this group. As a result, about half of the colonies we
observed on these screening plates carried the 51I/59R/108N
allele with no modification. In this control experiment, only
19 of 1100 colonies grew on the selective plates. The sequence
of the dhfr gene in these 19 colonies and in 20 colonies from
a plate with no drug was determined. No synonymous or non-
synonymous mutations were detected in any of these sequences;
all carried a dhfr allele with only the “parental” 51I/59R/108N
genotype and no additional mutations. In addition, only 2 syn-
onymous mutations were detected among 12,616 dhfr alleles se-
quenced from the Kenyan, Tanzanian, Malawian, and Gabonese
samples. The very low number of silent changes indicated that
the few mutations we did observe were most likely to have orig-
inated from the samples and did not result from high levels of
polymerase errors during the amplification.
The analysis of the isolates was done in 2 parts. First, the yeast
colonies were plated with no drug selection, and the dhfr was
sequenced from at least 5 independent colonies. These sequences
allow the identification of the predominant alleles in the sample,
including any alleles that carry simple polymorphisms unrelated
to drug resistance. The initial amplification of all 25 samples
collected before treatment was successful; 2 samples from the
Tanzanian set and 2 from the Nigerian set did not yield any
product after amplification of the sample collected on day 14.
The list of unselected genotypes in table 1 summarizes these data.
In 4 of the 5 locations, the triple-mutant allele (51I/59R/
108N) was clearly prevalent, and this genotype comprised 80%
of the alleles observed overall. Among the 3 patients from Kis-
arawe, Tanzania, 1 sample showed only the triple-mutant allele,
but the other 2 were predominantly wild type (wt). Four novel
alleles were observed; 1 patient from Tanzania and 1 from
Gabon each had a single allele that carried a mutation in ad-
dition to 51I/59R/108N. Two patients from Nigeria had a single
novel allele, and 1 patient carried 3 different alleles. We have
previously intensively mutagenized P. falciparum dhfr, to iden-
tify mutations that could encode a functional, resistant enzyme
[41, 42].
The transformed colonies were then arrayed on plates and
sequentially replica plated onto plates that contained 5104
mol/L pyrimethamine. This concentration permits robust growth
of yeast that depends on the highly pyrimethamine-resistant
Southeast Asian allele, 51I/59R/108N/164L, but inhibits the
growth of yeast colonies that carry only the 51I/59R/108N ge-
notype. Figure 2 shows an example of such an experiment. All
colonies that grew vigorously on the drug plates were isolated,
and the DNA sequence of dhfr was determined. Table 1 sum-
marizes these data, as well. As noted above, about half of the
colonies tested carried only the 51I/59R/108N genotype. The
most common new allele isolated, 51I/59R/108N/213A, was
observed in all sites except Tanzania. We observed 2 other alleles
that had been isolated previously from the field or in the lab-
oratory [42, 43]—a Kenyan allele with a fourth mutation at
codon 188 (51I/59R/108N/188K) and a Gabonese allele with a
change at 189 (51I/59R/108N/189R).
In contrast, the samples from Nigeria had 6 novel alleles with
numerous mutations. Two of these included the same 213A
mutation (51I/59R/108N/213A), and a third carried a N51I/
C59R/D91N/S108N/V213A genotype. Two other patients in the
Nigerian set each carried a novel quadruple-mutant allele, 51I/
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Table 1. Summary of the novel pyrimethamine-resistant alleles identified in the 5 African sites.
Site
Total
no. of
patients
Colonies with unselected genotypes Novel pyrimethamine-resistant genotypes
No.
Mutations found
without selection Total
N51I/C59R/S108N plus
single aa change Other genotypeswt 51/108 59/108 51/59/108
Kilifi, Kenya 6 6 10 7 42 … 65 N188K (day 0) and V213A
(day 14)
C59R/S108N/V213A (day 0)
Kasarawe, Tanzania 3 10 4 0 9 K19M 24 … …
Blantyre, Malawi 3 0 2 0 28 … 30 V213A (day 0) and V213A
(2) (day 14)
…
Lambare´ne´, Gabon 5 0 0 0 59 K56R 60 S189R V213A (day 14) …
Ibadan, Nigeria 8 0 10 0 80 E25G (x 2) T215A M92I 95 I200M V213A (day 0) and
P113L V213A I164V
(2) (day 14)
N51I/S108N/V213A
N51I/C59R/D91N/
S108N/V213A (day 0)
and C50Y/N51I/C59R/
E84K/V86M/S108N/
I164V (2) (day 14)
Total (%) 25 16 (5.8) 26 (9.4) 7 (2.5) 218 (79.5) … 274 … …
NOTE. Unselected genotypes are those identified by sequencing of the Plasmodium falciparum dhfr allele from at least 5 randomly chosen colonies.
Novel pyrimethamine-resistant genotypes are those observed in colonies that grew on the selective plates with mol/L pyrimethamine. Bold type4510
indicates mutations in addition to the triple mutant. aa, amino acid; wt, wild type; 2, mutation was found in 2 different samples.
59R/108N/164V, but the mutation at codon 164 differed from
the quadruple allele observed in Southeast Asia, 51I/59R/108N/
164L. In both patients, this 164V mutation was also observed
in combination with 3 additional changes, to produce an allele
with 7 differences from the wt (C50Y/51I/59R/E84K/V86M/
108N/I164V). To confirm that this highly mutant allele was not
generated by the PCR amplification, we performed a second in-
dependent amplification of 1 of these samples. The same highly
mutant allele was isolated in both analyses, making it extremely
unlikely that it is a PCR artifact.
The Nigerian samples also carried several silent substitutions
not seen elsewhere; 3 of 8 patients carried parasites with a
GAArGAG substitution at codon 202. Among these, 1 isolate
also carried a parasite with a silent GATrAAT change at codon
19, and another isolate carried a parasite with a TTGrTTA
change at codon 73. These numerous synonymous and non-
synonymous changes distinguished the Nigerian samples from
those at the other 4 sites. Since the polymerase and protocol
used for all of the samples were identical, this disparity also
suggests that the changes observed were not simply generated
by the PCR amplification.
On the basis of both the number of times we had isolated
an allele and our previous in vitro mutagenesis [41, 42], we
chose some of these alleles and performed IC50 assays to esti-
mate in yeast the level of drug resistance of the enzymes that
they encode. We determined the sensitivity of yeast dependent
on the canonical mutant dhfr alleles (51I/59R/108N and 51I/
59R/108N/164L) to pyrimethamine, chlorcycloguanil (the ac-
tive metabolite of chlorproguanil), and the experimental DHFR
inhibitor (WR99210) and compared them with novel mutant
alleles. Each yeast line was grown in 0–104 mol/L pyrimeth-
amine or chlorcycloguanil and 0–105 mol/L WR99210, and
the IC50 value (the concentration of drug that inhibited growth
of the yeast 50%, compared with the growth in the absence of
drug) was determined. Figure 3 shows average IC50 curves for
each allele analyzed. Figure 4A tabulates the actual IC50 values
for each drug, and figure 4B summarizes the fold change in
sensitivity between the triple mutant and each novel allele.
The plating screen was designed to identify yeast colonies
that were more resistant to pyrimethamine than the triple-
mutant allele, and the IC50 values show the expected trend: the
novel mutants confer a higher level of resistance to pyrimeth-
amine than the 51I/59R/108N allele. However, the IC50 values
of lines that carry alleles with 1 additional mutation (indicated
with bold type) at 213 (51I/59R/108N/213A) or 51I/59R/108N/
164V are roughly 3-fold higher, still substantially lower than
the 51I/59R/108N/164L, for which an IC50 value for pyrimeth-
amine cannot even be measured. Additional mutations in these
alleles (51I/59R/91N/108N/213A) or (C50Y/51I/59R/E84K/V86M/
108N/I164V) showed somewhat lower IC50 values, demonstrat-
ing that the additional mutations do not contribute to the
resistance to pyrimethamine. Only the alleles with a mutation
at codon 188 (51I/59R/108N/188K) or codon 189 (51I/59R/
108N/189R) showed resistance to pyrimethamine comparable
to that of the canonical quadruple-mutant N108/I51/R59/L164
allele; all 3 strains are so insensitive to pyrimethamine that an
IC50 value cannot be measured in this system.
As expected, the IC50 values for chlorcycloguanil were uni-
formly lower than those measured for pyrimethamine but fol-
lowed a similar pattern: the alleles with an additional mutation
at 213A or 164V were 13-fold more resistant to chlorcycloguanil
than 51I/59R/108N alone, and the additional mutations slightly
decreased resistance. The strains that carried the 188K, 189R,
and 51I/59R/108N/164L alleles were substantially more resistant
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Figure 2. A representative selective plate used to screen for pyrimethamine-resistant colonies. The dhfr coding region was amplified with PfuTurbo
polymerase (Stratagene) and inserted into the single-copy yeast plasmid by homologous recombination. All resulting colonies were arrayed as shown
without drug, and 5 were randomly chosen for determination of the dhfr sequence. The colonies were then sequentially replica plated onto plates with
mol/L pyrimethamine, and growth of each colony was assessed after 3 and 5 days at 30C. The “triple-mutant yeast” is dependent on the 51I/45 10
59R/108N genotype, and the triple +164L (51I/59R/108N/164L) mutant is the highly resistant mutant commonly found in Southeast Asia. The plasmid from
the single colony that grew on the selective plate was then isolated, and the sequence of the Plasmodium falciparum dhfr was determined.
than the strains carrying the triple mutants (51I/59R/108N) to
chlorcycloguanil, and, as observed for pyrimethamine, no IC50
value could be measured.
The experimental inhibitor WR99210 is extremely effective
against yeasts that carry P. falciparum dhfr alleles with3 mu-
tations [39, 41–43]. Even the canonical quadruple-mutant allele
is quite sensitive to WR99210; in yeast, it has an IC50 value of
∼ mol/L, compared with values in the mol/7 83 10 2–4 10
L range measured for the other alleles. All of the novel alleles
except 51I/59R/108N/188K and 51I/59R/108N/189R were also
extremely sensitive to WR99210, with IC50 values in the range
of 108 mol/L. Like the 51I/59R/108N/164L allele, strains that
depended on the 51I/59R/108N/188K allele were 10–20-fold
less sensitive to that inhibitor, with an IC50 value of ∼4107
mol/L. The 51I/59R/108N/189R allele conferred only a 6-fold
increase, with an IC50 value of mol/L.
71.3 10
In the present study, we isolated 10 novel alleles from 25
patients from a wide geographic area, and only the samples
from Nigeria yielded more than a few resistant alleles. In con-
trast, we previously identified 38 novel alleles with the same
method from only 6 isolates from a single location, Muheza,
Tanzania [43]. Table 2 compares these results directly.
The very small numbers of patients and the method we used
preclude a direct estimation of the prevalence of any particular
allele, but the paucity of novel alleles in the current data set is
clear. For example, 3 of the 6 patients from Muheza carried
the N51I/59R/108N/164L mutation, which is associated with
clinical failure of S/P in Southeast Asia. In this wider screen,
quadruple-mutant alleles with a 164V mutation were identified
in the Nigerian patients, but the 164L change was not observed
in any of the isolates identified in this screen.
DISCUSSION
In many sites in eastern and southern Africa, there has been a
rapid increase in the prevalence of the triple-mutant 51I/59R/
108N alleles associated with an increased risk of clinical failure
of treatment with S/P [3–16]. This trend is clearly reflected
here, as well; the triple-mutant allele was the most common in
4 of the 5 sites in which the trial was conducted, and this
genotype comprised ∼80% of the alleles sequenced in our study.
We designed the present study to identify rare dhfr alleles that
are likely to confer high levels of resistance to pyrimethamine.
The 17 isolates from 4 of the 5 sites in this study yielded only
4 novel resistant alleles, and only 2 of these (51I/59R/108N/
188K and 51I/59R/108N/189R) are in regions of the molecule
known to confer extremely high levels of resistance to pyri-
methamine [41, 42, 44]. The isolates from the fifth site, Nigeria,
did not follow this pattern. From the 8 Nigerian patients, we
isolated 6 highly mutant alleles, including a novel quadruple-
mutant allele with a mutation from isoleucine to valine at codon
164, carried by 2 different patients. Although the Southeast
Asian quadruple mutant carries a mutation at the same position,
that mutation encodes an isoleucine-to-leucine change. The en-
zymes encoded by the genotypes that carried the 164V change
did not confer levels of resistance comparable to the Southeast
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Figure 3. The sensitivity of yeast dependent on the novel dhfr alleles to pyrimethamine, chlorcycloguanil, and WR99210. Each strain was grown in
liquid in a 96-well plate with the indicated concentrations of each drug. After 18–24 h, the growth of yeast in each well was monitored by reading the
optical density at 650 nm. These curves show the average of 2–3 separate determinations, and the IC50 values in figure 4A were determined from the
graphs as shown. Because of the much higher potency of WR99210, the scales differ slightly in panel C; the highest concentration of pyrimethamine and
chlorcycloguanil used was 104 mol/L, but 105 mol/L was used for WR99210. SOLV, solvent alone (no drug).
Asian allele for any of the drugs tested. Overall, these results
suggest that alleles that confer high levels of resistance to anti-
folates are still rare in sub-Saharan Africa, even in eastern and
southern Africa, where pyrimethamine has been intensively used.
The very small numbers of patients and the method we have
used preclude a direct estimation of the prevalence of any par-
ticular allele, but the paucity of novel alleles in the current data
set, compared with the data from Muheza, is clear. In addition,
3 of the 6 patients from Muheza carried the N51I/59R/108N/
164L mutation, which is associated with clinical failure of S/P
in Southeast Asia. In this wider screen, quadruple-mutant alleles
with a 164V mutation were identified in the Nigerian patients,
but the 164L change was not observed in any of the isolates
identified in this screen.
Antifolate drugs have been used intensively in both areas for
longer periods than in most others in Africa, and there are high
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Figure 4. The comparison of drug sensitivity of selected alleles of Plasmodium falciparum dhfr to pyrimethamine, chlorcycloguanil, and WR99210. The
IC50 values for 2–4 experiments were calculated, and the average is reported in panel A. A graphical presentation of the fold change in sensitivity of each
novel allele, compared with the triple-mutant allele, (51I/59R/108N) is shown. †, The level of resistance to that drug was so high that no IC50 value could
be measured. B, Jagged bars, an IC50 value could not be measured, so the fold increase over the triple mutant allele could not be calculated.
levels of resistance to S/P in both areas [26, 45, 46]. The dom-
inance of triple-mutant alleles in all of the study locations makes
it clear that S/P-driven selection for mutant alleles of dhfr is
certainly in progress at all 5 locations, as well [14, 24, 47–50].
Whatever the selection pressure, the sites in Muheza and Ibadan
appear to have a deeper “reservoir” of alleles that are more re-
sistant to pyrimethamine than the triple mutant 51I/59R/108N,
compared with the sites in Kenya, Malawi, and Gabon.
Any method that requires PCR amplification runs the risk
of generating mutants simply from polymerase errors. Several
observations suggest that this has not been a problem in the
present study. First, the amplification of the triple-mutant allele
with the high-fidelity PfuTurbo polymerase produced no re-
sistant mutants in the 11000 colonies that we assessed, and
there was a striking paucity of silent substitutions. Second, 2
samples from patients in Tanzania had only wt parasites in the
nonselected colonies, and drug selection also yielded no resis-
tant alleles. Third, by use of in vitro mutagenesis, we have
previously generated a diverse set of alleles that can confer a
high level of resistance to pyrimethamine in this assay. This
result demonstrates that genotypes other than those observed
here could be generated by polymerase errors and isolated by
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Table 2. Comparison of screens of samples from 6 locations.
Variable
Muheza,
Tanzaniaa
Kenya, Tanzania,
Malawi, and Gabon Nigeria
Isolates screened, no. 6 17 8
Yeast colonies screened, no. 3994 12,616 7374
Novel alleles identified, no. 38 4 6
a Data are summarized from reference [34].
use of this method [42]. However, in these field samples, 1
allele, 51I/59R/108N/213A, was isolated in 4 of 5 sites and in
samples from 7 different patients, an unlikely occurrence if
these alleles were simply being generated at random during the
reaction. Finally, most of the alleles observed have a single new
mutation on a background of the common triple-mutant ge-
notype. These changes could not be generated by the poly-
merase “jumping” from 1 template to another during the am-
plification, another error that has been observed at low levels
in PCRs [51]. The highly mutant alleles from Nigeria could
have resulted from such an aberration, but the fact that the
same genotype was isolated from 2 individual patients and twice
during independent analyses of isolates from the same patient
greatly reduces the probability that these also are PCR artifacts.
Thus, we are confident that the novel dhfr alleles identified in
this screen were present at low levels in the samples.
One goal of the present study was to provide a baseline for
molecular surveillance of mutations in dhfr that are likely to
evolve in response to antifolate drug use. We have previously
used intensive mutagenesis in vitro to identify mutations of the
P. falciparum dhfr gene that encode functional, drug-resistant
forms of the enzyme [41, 42]. In both previous studies of dhfr
alleles isolated from patients’ samples, the same 2 regions of
the molecule with a disproportionate number of resistant mu-
tations have been identified: aa 188–191 and 213–215. Muta-
tions in aa 50–59, 108, and 164 are all observed frequently in
field isolates [43, 52]. Alleles with additional mutations in aa
188–191 or aa 213–215 have also been observed in vitro and
at low levels in the Muheza study [43]. The isolation of mu-
tations at codons 188 and 189 and at 213 in the current broader
sample follows this same pattern. Taken together, these data
suggest that it would be prudent to include assay of aa 188–
191 and aa 213–215 of the gene in a surveillance program de-
signed to provide early warning of selection of antifolate-resistant
populations of P. falciparum [18].
The sample set analyzed here derives from a single time point,
and a temporal study of changes in prevalence of rare resistant
alleles will be required to determine whether these alleles “in
the background” comprise raw material for selection by S/P.
High-throughput methods with greater sensitivity than the cur-
rent allele-specific PCR methods will be needed to identify re-
sistant alleles even when they are at low prevalence, and some
steps have already been made in that direction [15, 53–55].
Recent molecular studies show that, in highland areas of low
transmission close to Muheza, the triple-mutant alleles of dhfr
share the same extended haplotype, suggesting that a single
triple-mutant allele of dhfr has invaded the P. falciparum pop-
ulation and spread under drug selection [56]. More-extensive
studies in Southeast Asia and South America support this “se-
lective sweep” model of the selection process [57, 58]. This
outcome is surprising, since the increasing resistance to pyri-
methamine requires simply the acquisition of 1 additional point
mutation after another, and one might have predicted that
mutant alleles could arise repeatedly in situ on many different
haplotypes. The sample set analyzed here derives from a single
time point, and a temporal study of changes in prevalence of
rare resistant alleles will be required to determine whether these
alleles “in the background” comprise raw material for selection
by chlorproguanil-dapsone.
Chlorproguanil-dapsone has recently been introduced in a
number of African countries, including those in the present
study [34]. As yet, there are no clinical data that would allow
us to assess whether the modest increases in resistance to chlor-
cycloguanil that we observed in the yeast system would com-
promise the clinical efficacy of chlorproguanil-dapsone. How-
ever, the set of mutations that confer high levels of resistance
to chlorcycloguanil overlaps substantially with the set of mu-
tations that confer resistance to pyrimethamine [42, 59], so
selection of any of these novel alleles would certainly head in
the wrong direction. On the basis of the results of the present
study, only the N108/I51/R59/188K and the N108/I51/R59//
S189R alleles are likely to substantially increase resistance to a
level comparable to that of the 51I/59R/108N/164L allele [35].
Each of these alleles was found only once, suggesting that there
may not yet be a reservoir of these alleles, at least in the sites
tested in the phase 3 trial.
The biguanide prodrugs of the WR99210 class are currently
in preclinical development [60, 61], and the excellent effec-
tiveness of WR99210 against all of the alleles examined here is
encouraging. On the basis of the data reported here, we would
expect that none of the alleles we isolated would show serious
levels of resistance to drugs of the WR99210 class; definitive
information on this conclusion will depend, of course, on direct
clinical trials.
What can we learn from a limited “snapshot” of this kind?
Such a small sample cannot be extrapolated to general predic-
tions about resistance to antifolates in the sites at which the
original study was done and certainly cannot be expanded to
conclusions about nearby locations. Variation even within geo-
graphically or temporally related sites is far too high for those
kinds of predictions to be reliable [15, 62–64]. However, our
approach does allow qualitative comparisons, and it identifies
locations such as Muheza and Ibadan, where there has been
apparently strong selection for antifolate resistance in the past.
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In the sites sampled in Kenya, Tanzania, Malawi and Gabon, S/
P has been used for almost 10 years, and the triple-mutant allele
is prevalent. Under these circumstances, the low “harvest” of
resistant alleles is encouraging. This suggests that the combina-
tion of chlorproguanil-dapsone may have a reasonably useful
therapeutic life in those locations. The presence of these alleles
underlines the importance of developing and implementing sen-
sitive, high-throughput methods and of creating and maintaining
regional databases to serve as better early warning systems for
the emergence of alleles associated with drug resistance.
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